Tonn J C, Ott M M, Bouterfa H, Kerkau S, Kapp M, Müller-Hermelink H K, Roosen K
Department of Neurosurgery, University of Würzburg, Germany.
Neurosurgery. 1997 Nov;41(5):1152-9. doi: 10.1097/00006123-199711000-00027.
The progesterone receptor (PgR) can be detected in 60 to 70% of meningiomas using immunohistochemistry] in situ. Whereas in monolayer tissue cultures the PgR is only rarely expressed, we were able recently to demonstrate the preservation of the PgR in fragment spheroid cultures of meningiomas. The aim of the present study was to evaluate the stability of PgR expression in meningioma spheroids in vitro and the correlation of PgR expression and cell proliferation in spheroids and whether meningioma cells reaggregated to spheroids from monolayer cultures to reexpress the PgR again.
Tumor fragment spheroids (Weeks 1-6) and cell monolayers (Passages 1 and 3) of 15 PgR-positive meningiomas were investigated by immunohistochemistry for the expression of PgRs and their proliferative activity, as demonstrated by positivity for the proliferation-related antigen Ki-67. To study PgR reexpression in reaggregated spheroids, Northern blots were performed. In addition, a reverse transcriptase-polymerase chain reaction technique was established and evaluated in combination with immunohistochemistry. Growth of meningioma spheroids was quantified in the presence of progesterone and the specific antagonist onapristone.
The PgR remained stable in spheroids for 6 weeks in 9 of 13 cases that were able to be evaluated. All tumor fragment spheroids exhibited a proliferation index of 5 to 40% Ki-67-positive cells. Monolayer cell cultures, on the other hand, failed to express PgRs but revealed higher proliferation indices (40-90%) to a significant extent. The detection of PgR messenger ribonucleic acid in reaggregated spheroids by means of reverse transcriptase-polymerase chain reaction correlated to the nuclear expression of PgR in immunohistochemistry. Neither progesterone nor its antagonist onapristone altered spheroid growth in vitro.
The expression of the PgR in meningiomas is preserved in spheroid cultures with low proliferation indices for at least 6 weeks, whereas monolayer cell cultures with a high proliferative activity lack PgR expression. The inverse pattern of Ki-67-positive cells in the outer regions of the spheroids and PgR-expressing tumor cells in the spheroid centers leads us to the conclusion that proliferating meningioma tumor cells do not express PgRs. This might also explain why tumor cell growth in vitro was neither affected by progesterone nor by onapristone. Monolayer cell cultures can be reaggregated to spheroids, the consequence being a reexpression of PgRs and, therefore, a down-regulation of proliferation.
采用免疫组织化学原位检测法,在60%至70%的脑膜瘤中可检测到孕激素受体(PgR)。而在单层组织培养中,PgR很少表达,最近我们能够证明在脑膜瘤的碎片球体培养中PgR得以保留。本研究的目的是评估体外脑膜瘤球体中PgR表达的稳定性、球体中PgR表达与细胞增殖的相关性,以及脑膜瘤细胞是否从单层培养重新聚集形成球体以再次重新表达PgR。
对15例PgR阳性脑膜瘤的肿瘤碎片球体(第1 - 6周)和细胞单层(第1代和第3代)进行免疫组织化学检测,以检测PgRs的表达及其增殖活性,增殖相关抗原Ki - 67阳性可证明其增殖活性。为研究重新聚集球体中PgR的重新表达,进行了Northern印迹分析。此外,建立并结合免疫组织化学评估了逆转录聚合酶链反应技术。在存在孕激素和特异性拮抗剂奥那司酮的情况下,对脑膜瘤球体的生长进行定量分析。
在13例能够进行评估的病例中,有9例PgR在球体中保持稳定达6周。所有肿瘤碎片球体的增殖指数为5%至40%的Ki - 67阳性细胞。另一方面,单层细胞培养未能表达PgRs,但在很大程度上显示出更高的增殖指数(40% - 90%)。通过逆转录聚合酶链反应在重新聚集球体中检测到的PgR信使核糖核酸与免疫组织化学中PgR的核表达相关。孕激素及其拮抗剂奥那司酮均未改变体外球体的生长。
脑膜瘤中PgR的表达在增殖指数较低的球体培养中至少保留6周,而具有高增殖活性的单层细胞培养缺乏PgR表达。球体外部区域Ki - 67阳性细胞与球体中心表达PgR的肿瘤细胞的相反模式使我们得出结论,增殖的脑膜瘤肿瘤细胞不表达PgRs。这也可能解释了为什么体外肿瘤细胞生长既不受孕激素影响,也不受奥那司酮影响。单层细胞培养可以重新聚集形成球体,结果是PgRs重新表达,从而增殖下调。